GENSIGHT Aktie

 

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 1,999,998.1515 fundraising (the "Fundraising"). The Fundraising resulted in the issuance of: (i) 15,980,844 ordinary shares (actions ordinaires) of the Company (the "Offered Shares"), which were admitted to trading on Euronext Paris on November 12, 2025 (ISIN FR0013183985/SIGHT); (ii) 3,492,063 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 3,492,063 additional ordinary shares; and (iii) 19,472,907 warrants (the "Offered Investor Warrants") giving the right to subscribe to 19,472,907 additional ordinary shares. The...

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics ("GenSight" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a EUR 1,999,998.1515 fundraising subscribed by two investors which were existing shareholders: Invus and Alumni Capital (the "Fundraising"). This fundraising follows the EUR 4.5 million private placement completed in July (in two tranches) and the EUR 3.7 million fundraising completed in early October. The Fundraising uses the same structure of shares and warrants, including pre-funded warrants, as detailed further below. "Our strategy to move the development of GS010/LUMEVOQ forward has continued to p...

Cash position amounted to €0.6 million as of September 30, 2025 Successful closing of fundraising worth nearly EUR3.7 million on October 1, 2025 Cash position amounted to €3.6 million as of October 1, 2025 PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2025. Cash Position and Outlook GenSight Biologics' cash and cash equivalents totalled €0.6 million as of September 30, 2025, compared to €0.3 million as of June 30, 2025. On October 1, 2025, the company received the net proceeds from the fundraising completed on September 26, 2025, totaling €3.0 million, net of the repayment of €0.7 million principal on the convertible bonds held by Heights Capital. As...

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 3,694,665.92 fundraising (the “Fundraising”). The Fundraising resulted in the issuance of: 18,816,666 ordinary shares of the Company (the "Offered Shares"), which were admitted to trading on Euronext Paris on September 30, 2025 (ISIN FR0013183985/SIGHT); 13,060,600 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 13,060,600 additional ordinary shares (the "Pre-Funded Warrant Shares"); and 31,877,266 warrants (the "Offered Investor Warrants") giving the right to su...

Optimized cash management results in 8.3% reduction in operating cash outflow compared to the same period in 2024 Cash runway extended to late Q4 2025 following post-closing financing Manufacturing process transfer to Catalent, Inc., on track Protocol for the dose-ranging study submitted to the ANSM in mid-August PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2025. The 2025 half-year financial statements were subject to a limited review by the Company's statutory auditors and approved by the Board of Directors on September 26, 2025. The full interim financial report is available on the Company's website in the Investors section. “We have rigorously maintained financial discipline in the first half of 2025...

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a EUR 3,694,665.92 fundraising subscribed by three of its shareholders: Heights Capital, Invus and Alumni Capital (the “Fundraising”). This fundraising follows the EUR 4.5 million private placement completed in early July and uses the same structure of shares and warrants, including pre-funded warrants, as detailed below. “As ever, we are grateful to our three existing shareholders for their continued confidence in the strategy we have built and the roadmap we are following.“ said Laurence Rodriguez, Chief Executive Officer of GenSi...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the release of its half-year financial results, originally scheduled for September 19, 2025, has been postponed to September 29, 2025, after the market closes. The postponement allows the Company's external auditors to complete all necessary audit procedures to the highest professional standards. The Company confirms that the postponement relates only to the time required for the audit rather than to any material issues with the financial statements. The extension permits full compliance with regulatory requirements and maintains the Company's commitment to accurate and transparent financial reporting. The Company's Audit Committee and Board of Directors meetings ha...

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced a financing through a capital increase reserved to an existing shareholder by the issuance of new shares with warrants attached, for a total gross amount of EUR 499,999.92 (excluding the future net proceeds related to the exercise of the warrants) (the "Reserved Offering"). The subscription price for one ABSA is EUR 0.17 (the "Offering Price"). This follows the approximately EUR 4 million financing announced on July 1, 2025 (the “Early July Financing”). The Offering Price of the ABSA and the terms and conditions of the warrants, including their ...

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 3,908,715.39 private placement (the “Private Placement”). The Private Placement resulted in the issuance of 21,251,267 ordinary shares of the Company (the "Offered Shares"). The Offered Shares will be admitted to trading on Euronext Paris on July 3, 2025 (ISIN FR0013183985/SIGHT). The issuance of: The 1,850,000 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 1,850,000 additional ordinary shares (the "Pre-Funded Warrant Shares"); and The 23,101,267 warrants (the "Offer...

PARIS--(BUSINESS WIRE)--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful completion of a private placement of EUR 3,908,715.39 subscribed by a limited number of investors (the “Private Placement”). “We would like to thank our existing shareholders for their continued support, as well as the new international investors who have joined us in this important financing round,” commented Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. “The investment reflects the market's recognition of GenSight's unique position and the significant potential of our therapeutic programs. With this funding, we remain w...

PARIS--(BUSINESS WIRE)--Regulatory News: The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, took place on May 13, 2025, at 2:00 pm CEST at the Company's headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting was chaired by Laurence Rodriguez, Chief Executive Officer of the Company. All resolutions recommended by the Board of Directors and submitted to the Combined General Meeting were adopted, with the exception of Resolution A, which was rejected, in accordance with the recommendations of the Board. The quorum on first convening amounted to 56.51%. During the General Meeting, the Chief Executive Officer reviewed the key achievements of 2024, a year marked by careful cash management, strengthened financial structure with the participati...

Procedures for obtaining preparatory documents for the General Meeting PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 13, 2025, at 2:00 pm CEST at the Company's headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France. The General Meeting will also be webcast live for shareholders on at the following link: https://channel.royalcast.com/landingpage/gensightbiologicsfr/20250513_1/. The notice containing the agenda and draft resolutions was published in the French BALO on April 7, 2025. The notice confirming the time and place of the meeting was published in the French BALO and in a legal gazette on April 23, 2025. The preparatory documents for the General Meeting listed in Article R. 22-10-23 of the Fren...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today confirmed that its definitive annual results for the fiscal year ended 2024 are in line with the estimated figures published on February 27, 2025. Confirmation of Results The definitive consolidated and individual accounts, which were reviewed by the Audit Committee on March 17, 2025, and approved by the Board of Directors on March 18, 2025, confirm the following key financial indicators as previously estimated: Annual Consolidated Financial Statements (IFRS) Item 2024 Definitive 2024 Estimated 2023 Definitive (€ million) (€ million) (€ million) Operating Income 2.6 2.6 3.0 Operating Profit (loss) (15.8) (15.8) (29.7) Financial Profit (loss) 1.8 1.8 3.5 Net profit (loss) (14.0) (14.0) 26.2 Cash and Cash equivalent 2....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Review of LUMEVOQ® dossier to resume compassionate access program in France is ongoing; in parallel, work continues on the new RECOVER Phase III clinical trial and marketing application to the MHRA Cash runway extended to early April 2025 thanks to active cash management and the expected collection of Research Tax Credit (CIR) in March Resumption of the Compassionate Access Program (AAC) is now expected to occur in April 2025 PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported estimated full-year 2024 consolidated financial results1, as reviewed by the Audit Committee and approved by the Board of Directors on February 26, 2025. The Board of Directors will approve the final accounts on March 18, 2025, and the final certification by the auditors will take place afte...